Inside Sep 2015
New eLearning
FAQs
Manual Update
Quick Links
Greetings!

After a summer break most grade school students return refreshed and eager to learn. While adults rarely are as enthused about workplace training because it takes time away from doing the work to learn about the work. If it happens to be a subject matter that they think they already know then motivation to do the training is even more difficult and seen as a waste of their time.

Here's the caveat. CIBMTR data needs are never static. There is often something new we're asking for. Something new to learn.

What can your team do to help motivate all of your data managers to take time out for CIBMTR Training? Do you have a team environment that supports and encourages excellence in data collection and reporting? What about trying incentives? Using eLearning completion and test passing for annual goal planning and professional development?  

We currently have numerous training modules in development. The result will be even more materials for you in the Learning Center soon. Without bias, the content of each module is going to be worth your time. 

We thank you for every minute you spend learning with us.

CIBMTR Training
CIBMTR is a research collaboration between the NMDP/Be The Match and Medical College of Wisconsin.
New eLearning this month
"Infusion Data (Form 2006) Reporting Overview" 
This module was authored by Alisha Mussetter, Katie Newcomb, and Jenni Bloomquist. It provides a high level overview of the Form 2006 including appropriate completion of the form. It is approximately 25 minutes in length. Following completion of the eLearning is an exam to be taken with the Form 2006 Instruction Manual open. You will find this eLearning in our Learning Center, under the category CIBMTR Data Management. Subsequent modules in development will further explain product analysis and product identifiers.
 
Question: Reporting on the Pre-TED (Form 2400) - Myelofibrosis
A patient was diagnosed with Essential Thrombocytosis (ET) in the year 2000 and received treatment with Anagrelide. In 2014, the patient developed pancytopenia. A BMBx was obtained & it documented myelofibrosis.  How should this be reported on the Pre-TED (Form 2400)?

Answer:
Some patients with Essential Thrombocytosis (ET) may develop marrow fibrosis (myelofibrosis) as a later stage of the disease. This type of myelofibrosis would be considered secondary and should not be reported as primary myelofibrosis. The correct diagnosis to report at transplant is ET.  One should not report the development of myelofibrosis as a transformation. In other words, Question #525 on the Pre-TED (Form 2400) should be answered "no".
Send your questions into CIBMTRTraining@nmdp.org The answer may be in a future newsletter.

Thank you to the contributors for this month's newsletter.
CIBMTR Training